Moors & Cabot Inc. boosted its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 235.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 100,750 shares of the medical equipment provider’s stock after purchasing an additional 70,740 shares during the quarter. Moors & Cabot Inc.’s holdings in Boston Scientific were worth $4,398,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors also recently bought and sold shares of the company. Clal Insurance Enterprises Holdings Ltd acquired a new position in shares of Boston Scientific in the 1st quarter valued at about $28,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Boston Scientific during the 1st quarter valued at about $32,000. Measured Wealth Private Client Group LLC lifted its position in Boston Scientific by 244.9% during the 1st quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 387 shares in the last quarter. Kelleher Financial Advisors acquired a new position in Boston Scientific during the 2nd quarter worth approximately $25,000. Finally, Nvwm LLC boosted its holdings in Boston Scientific by 526.2% in the 3rd quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 542 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.
Analyst Upgrades and Downgrades
Several analysts have issued reports on BSX shares. JPMorgan Chase & Co. downgraded shares of Boston Scientific from an “overweight” rating to a “neutral” rating and set a $46.00 price objective for the company. in a research report on Wednesday, October 28th. Rothschild & Co Redburn reduced their target price on shares of Boston Scientific from $106.00 to $78.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Sanford C. Bernstein decreased their target price on shares of Boston Scientific from $54.00 to $49.00 and set an “outperform” rating for the company in a research note on Thursday, October 29th. Oppenheimer lowered shares of Boston Scientific from an “outperform” rating to a “market perform” rating in a report on Thursday, October 29th. Finally, Piper Sandler dropped their price target on shares of Boston Scientific from $65.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $61.43.
Check Out Our Latest Analysis on BSX
Boston Scientific Stock Performance
Shares of BSX stock opened at $44.33 on Monday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.81 and a current ratio of 1.36. Boston Scientific Corporation has a one year low of $39.57 and a one year high of $104.61. The company’s 50-day simple moving average is $44.00 and its 200-day simple moving average is $54.50. The stock has a market capitalization of $64.25 billion, a price-to-earnings ratio of 18.78, a PEG ratio of 1.31 and a beta of 0.60.
Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, meeting the consensus estimate of $0.73. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. Boston Scientific’s quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.75 earnings per share. Equities analysts anticipate that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.
About Boston Scientific
Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.
Recommended Stories
- Five stocks we like better than Boston Scientific
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
